Defining the infrastructure for post-ISS pharmaceutical research.
The landscape of orbital research is undergoing an epochal transition. As the International Space Station (ISS) nears the completion of its fundamental role as a testbed, the industry is looking toward new commercial orbital platforms. This shift is not merely logistical but operational: it requires a redefinition of the infrastructure necessary to sustain large-scale R&D and pharmaceutical manufacturing. The Fedegari Universe stands at the center of this dialogue, facilitating the move toward next-generation platforms that allow for continuous, safe research integrated directly into the pharmaceutical value chain.